Skip to main content

CASE REPORT article

Front. Oncol., 06 June 2024
Sec. Head and Neck Cancer

Primary malignant melanoma of the parotid gland, a rare case arising from a duct: a case report and literature review

Moe Thu Zar Aung,Moe Thu Zar Aung1,2Jo-Eun Kim*Jo-Eun Kim1*Hye-Jung YoonHye-Jung Yoon3Kyoung-Hoe HuhKyoung-Hoe Huh1Won-Jin YiWon-Jin Yi1Min-Suk HeoMin-Suk Heo1Sam-Sun LeeSam-Sun Lee1
  • 1Department of Oral and Maxillofacial Radiology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea
  • 2Department of Oral Medicine, University of Dental Medicine, Mandalay, Myanmar
  • 3Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea

Malignant melanoma of the parotid gland is an unusual tumor in the head and neck region, and most parotid melanoma is reported as a metastatic lesion of cutaneous malignant melanoma. We report a case of primary malignant melanoma arising in the parotid gland duct with diagnostic challenge. The patient was a 68-year-old man who complained of repeated right facial swelling that presented 3 months prior. Swelling was detected along the Stensen’s duct of the cheek, and brown-colored saliva-like fluid was aspirated. On MR and CT images, a fluid-filled duct with small nodule and heterogeneously enhancing mass in the parotid parenchyma was detected. The nodular mass on the ductal wall grew rapidly, and the hyperintense T1 signal became significant on follow-up images. The final diagnosis via histopathologic examination using biopsy and parotidectomy specimen revealed the lesion as malignant melanoma of the duct and pleomorphic adenoma of the parenchyma. Even if the incidence of primary malignant melanoma is very low among tumors occurring in the parotid gland, efforts supporting an early diagnosis using imaging characteristics are important.

Introduction

Malignant melanoma (MM) is a malignant tumor of uncontrolled replication of pigment-producing melanocytes within the skin epidermis. Cutaneous melanomas are the most common type of melanoma in the head and neck region (85%~90%), whereas mucosal melanoma also can arise in the oral cavity (1). MM rarely affects the parotid gland and presents as a progressively enlarging, asymptomatic, firm, and fixed parotid mass. These parotid melanomas are assumed to originate from intraparotid lymph node metastasis, which primarily arises from skin neoplasm of the head and neck (24).

The origin of primary MM can be difficult to determine or may never be identified (5), indicating the possibility of primary MM of the parotid gland. In addition, the presence of melanocytes in the normal parotid gland supports the possibility of primary MM of parotid glands (6, 7). Although rare, some studies reported primary MMs of the parotid gland characterized by poor prognosis and difficult delayed diagnosis (810). However, there has been no report of MM in the parotid duct until now.

In general, clinical findings such as pigmentation could act as a pathognomonic finding when diagnosing cutaneous melanoma. In the case of parotid MM, which does not have the crucial clinical sign of pigmentation, help with radiologic or pathologic examination is urgently needed. Diagnostic imaging is useful for identifying MM because melanoma shows hyperintense signal intensity on T1-weighted images due to the presence of melanin (11).

The following case describes a primary MM thought to have originated from the parotid gland, especially the duct, and that involved diagnostic difficulties due to an incidentally concurrent parenchymal parotid mass. In this case report, CT and MRI features of primary MM will be reviewed throughout the literature.

Case presentation

A 68-year-old male patient visited the neurosurgery (NS) department with repeated right facial swelling along the Stensen’s duct that first presented 3 months prior. The patient had no other specific underlying disease. Before visiting this hospital, he had undergone several procedures to drain the fluid from the duct in the local clinic, but the swelling returned each time. There were no neurological abnormalities, and NS surgeon referred the patient to the department of oral and maxillofacial surgery (OMFS) under the clinical diagnosis of obstructive sialadenitis due to sialolith. Salivation via a duct orifice was confirmed upon massaging the parotid gland, and aspiration confirmed a brown-strawberry–colored, non-mucous fluid with hemosiderin precipitate. The OMFS surgeon diagnosed the mass as a parotid duct cyst with vascular malformation and phlebolith.

In the initial MR image, prompt dilation filled with hyperintense T2, non-enhancing signal of right Stensen’s duct was confirmed, and a hypointense nodular focus was observed in the duct orifice region (Figures 1A–D). Some small nodular foci were detected in the dilated ductal wall, and these nodules showed hypointense T2 and enhancement signals. In addition, in the parotid parenchyma, an enhancing mass was found, and the mass showed heterogeneous hyperintense T2 and hypointense T1 signal intensity (Figures 1E–H). The low-signal nodule at the orifice was thought to be sialolith causing obstruction and sialadeitis in the NS (Figures 1A, B). However, it also could be regarded as phlebolith combined with venolymphatic malformation, considering the parenchymal lesion as part of the same lesion. PET-CT images showed minimal hyper-uptake in the parotid parenchyma, hindering a malignancy diagnosis (Figure 1H).

Figure 1
www.frontiersin.org

Figure 1 Images of initial imaging examinations. Axial MRI with fat-suppressed T2-weighted image (A, E), T1-weighted image (B, F) fat-suppressed contrast-enhanced T1-image (C, G), and PET-CT images (D, H). Dilated duct filled with fluid signal, and small nodules on the ductal wall show slight hyperuptake on PET image (A, D, arrowhead). Note the small focus at the orifice region with hypointense T2 and hyperintense T1 signal (A–C, dotted arrow). A heterogeneous mass with enhancement on contrast-enhanced MRI (G) and slight hyperuptake on PET (H) in the parenchyma were detected (E–H, arrow). Nodules on ductal wall and parenchymal mass showed different signal entity.

In the contrast-enhanced CT images obtained after a month, nodular enhancing masses along the dilated ductal wall were confirmed (Figure 2A), but there was no calcified focus at the orifice (Figure 2B). The heterogeneously enhancing parenchymal mass showed a mixture of highly attenuated areas similar to vessel and a low attenuated lesion with faint margin (Figure 2C). Considering the MR/CT images and clinical findings, the clinical diagnosis of OMFS surgeon was venolymphatic malformation.

Figure 2
www.frontiersin.org

Figure 2 Contrast-enhanced CT images obtained after 1 month (A–C). Nodular enhancing masses along the dilated ductal wall were enlarged (A). No calcified focus at the orifice region on bone filtered reconstruction (B) dotted arrow. Parenchymal lesion showed heterogeneous enhancement (C) white arrow. Pre-operative images (the images 3 months after the initial MR) of axial fat-suppressed T2-weighted MR image (D), T1-weighted MR image (E), contrast-enhanced CT images of axial (F), and coronal (G). An enlarged ductal wall and enlarged nodular mass (arrowheads) were confirmed (D–F). Note the hypointense T2 signal and hyperintense T1 signal of ductal wall melanoma (D, E). Coronal contrast-enhanced CT image shows an enlarged ipsilateral cervical lymph node that is revealed as metastasis (black arrow, (G).

Intra-oral open biopsy via the orifice region of the buccal cheek mucosa was performed. When the incision and slight dissection were performed, a black tumor nodule was revealed and sent to the oral pathology department. The OMFS surgeon confirmed no pigmentation in the intraoral mucosa near the orifice. Histopathologic examination confirmed the biopsy specimen as MM.

Screening of other sites especially the head and neck skin was performed but showed no pigmented lesion. On pre-operative CT and MR images obtained 3 months after the initial imaging, the nodular lesion on the ductal wall was enlarged (Figure 2D), the hyperintense T1 signal (Figure 2E) and enhancement (Figure 2F) became remarkable. In addition, a positive lymph node not detected in the previous exams was enlarged to level IIa (Figure 2G). However, the parenchymal mass showed no change in size or characteristics.

The operation including Mass excision with total parotidectomy, selective neck dissection, latissimus dorsi muscle free flap, and facial nerve repair with sural nerve graft was performed. In the specimen sent to the oral pathology department, two different lesions in the parotid gland were confirmed histopathologically. One was a tumor mass that had grown into the lumen from the epithelium of an enlarged salivary gland duct (Figures 3A, B, E). The tumor cells had dark brown melanin pigments in hematoxylin-eosin staining (Figure 3F) and showed diffuse positive immunoreactivity for HMB-45 (Figures 3C, G). The remaining ductal epithelial cells of the affected duct were positive for cytokeratin 7 (Figures 3D, H). The other mass is a pleomorphic adenoma that existed in the deeper part of the parotid gland. Therefore, the final diagnosis was MM of the salivary duct accompanied by pleomorphic adenoma. Ipsilateral lymph node metastasis of MM was confirmed at levels Ib and IIa.

Figure 3
www.frontiersin.org

Figure 3 Representative histopathologic features strongly suggesting that malignant melanoma originated from the ductal epithelium. (A, B) Malignant melanoma of the parotid duct. Intraluminal masses arising from the ductal epithelium. (C) Large polygonal tumor cells had melanin pigments and immunoreactivities for HMB-45. (D) The remaining ductal epithelial cells were detected by the immunostaining with cytokeratin 7 (black arrows). (E) Tumor masses (asterisk) arising from the ductal epithelium (scale bar = 3mm). Inserted box area is magnified and shown in (F–H). (F) Hyperchromatic, atypical cells were observed in the ductal epithelium. (G) Proliferating atypical melanocytic cells in the epithelium were positive for HMB-45. (H) The intact ductal epithelial cells were positive for cytokeratin 7. Hematoxylin and eosin staining (A–C, E, F) and immunohistochemical staining (D, G, H); Olympus BX45 microscope; Spot image capture software (Spot Imaging, Sterling Heights, MI, USA). HMB45.

Post-operative radiation therapy and chemotherapy were performed as adjuvant treatments. The rehabilitation treatment for facial paralysis continues. Although the patient complained of reduced function in trigeminal and facial nerves (altered sensation and impaired eyebrow movement), there was no evidence of local recurrence on follow-up CT, MR, or PET images up to 13 months after the operation.

Discussion

Tumors of the salivary glands are rare, accounting for less than 3% of all head and neck neoplasms. Off all salivary gland tumors, 80% develop in the parotid gland and 25% of those are malignant (12). The parotid gland itself can act as the filtering station for lymphatic drainage in the head and neck. Therefore, malignancy of the head and neck region most commonly leads to metastasis to the parotid gland. A previous study reported that about 80% of parotid metastasis are assumed to originate from a cutaneous malignancy of the upper face and scalp (13).

MM of the parotid gland is very rare, and there remains controversy regarding its origin. Generally, MM is thought to form through lymph node drainage from cutaneous melanoma of head and neck primary cancers. However, the primary tumor source can be difficult to determine. About 10% to 35% of melanomas show regression and resolve completely. Some studies suggest that regressed MMs are more likely to metastasize (14). The majority of previously reported cases of primary parotid MM appears to represent metastasis within the intraparotid lymph node. Regression of primary cutaneous melanoma can occur through autoimmune surveillance.

However, many studies claim that melanocytes originally exist in a gland, which can give rise to MM with a primary origin. In a prior study, Takeda found melanocytes in the interlobular duct of the parotid gland during an autopsy on a Japanese male; melanocytes derive embryologically from the neural crest and do not usually form part of the salivary tissue (6). On the other hand, Greene and Bernier reported that the parotid gland may also contain melanoblasts because it develops from invaginating buccal epithelium that could contain melanoblasts and pointed out the presence of melanin within ductal and acinar cells. They also described primary MM as infiltrative, resulting in poorly demarcated tumors and not located in lymph nodes (7).

To diagnose primary MM of the parotid gland, the following criteria proposed by Woodward et al. should be met (15):

[1] The tumor mass is located within the parotid gland.

[2] The tumor does not contain any identifiable lymph node tissue.

[3] There is no evidence of other MM lesions in the body.

[4] There is no evidence of previous MM excision or progression of suspicious pigmented lesion.

The present case satisfies these four criteria and, unlike other cases, showed characteristic features above within a duct. Metastatic MM should involve the parenchymal lymph node but not the duct, supporting diagnosis of this lesion as primary MM of the parotid gland. Moreover, there was another primary mass (revealed as pleomorphic adenoma) in the parenchyma, hindering diagnosis using CT and MR images. Considering the entire diagnostic process, the MM of this case was thought to have arisen from the parotid ductal tissue and grown in the inner space of the main duct. It is possible that the mass originated from the oral mucosal tissue of the orifice and grew retrograde into the duct, although this possibility is low because the surgeon confirmed no pigmentation in the oral mucosa, including the orifice region. MM arising from a parotid duct has not been previously reported.

We reviewed papers in PubMed and Google Scholar using the keyword “parotid malignant melanoma.” Among the papers published since 1960, only English articles were reviewed, and cases of metastasis from an unknown primary site to the parotid LN were excluded. Table 1 summarizes the clinical and imaging features from the documents.

Table 1
www.frontiersin.org

Table 1 Summary of literature review of primary malignant melanoma of the parotid gland.

Most of the patients had non-specific symptoms such as parotid swelling, and the lesion size was large (3.5 cm to 12 cm) considering the symptom duration. All tumors occurred in the parenchyma and were located in some parts of the superficial lobe, or they replaced the entire parotid. However, there was no case located in the duct. Immunohistochemical staining, such as S-100 and HMB-45, was additionally performed for accurate diagnosis, and the possibility of melanoma in other regions was evaluated and excluded to prove primary MM.

In cases having images or description of images, the margins were relatively well-defined, and the internal view showed homogeneous or heterogeneous attenuation on CT imaging. Therefore, most of them were not clearly distinguished from benign salivary gland tumors such as pleomorphic adenoma, making it difficult to detect MM before biopsy. Although the patient number is small, hints of diagnosis were obtained from iso to high T1 signal in cases where MR was performed (10, 17), including this case. Hyperintense T1 signal in the MM indicated the paramagnetic effect of melanin and its accompanying hemorrhage (20). In this way, when diagnosing salivary gland tumor, MRI can not only provide information about the relationship between tumor and facial nerve for surgery but also contribute greatly to the diagnosis of rare diseases such as MM, so MRI is strongly recommended for diagnosing salivary gland tumor.

The treatments for primary MM of parotid gland were based on resection of the lesion, such as parotidectomy, and, sometimes, radiation therapy, chemotherapy, or immunotherapy were added. Metastasis to other sites was identified in 67% (8/12) of cases, except for follow-up loss cases and patients without metastasis having better prognosis [more NED (no evidence of disease) than DOD (died of disease), and longer follow-up (FU) duration]. In this review, most patients died of disease in the period of 2 to 48 months. We only reviewed the cases that insisted “primary” MM of parotid gland. According to previous studies, the prognosis of unknown primary parotid MM was better than known cutaneous MM, and the 5-year survival rate was more than 50% (21, 22). A full-scale comparative study on primary MM originating in the parotid gland and lesions metastasized to the parotid gland has not yet been conducted due to the small number of cases. However, based on this literature review, the two lesions may have different prognoses, so early exact diagnosis, more aggressive treatment methods, and closed follow-up may be needed for primary lesions.

Despite various arguments, there are also papers denying that primary MM originates in the parotid gland. In this case report, the absence of melanoma in other LNs or skin that could be assumed to be the primary lesion was not pathologically proven, so the possibility of occult skin melanoma in other areas cannot be completely ruled out. However, this case is very unique and has findings that suggest that it occurred within the duct, so it is worthy of reporting. Although the possibility of parotid primary MM is low, early diagnosis is very important. In the case of parotid mass, imaging exams were used for diagnosis and surgical planning. At this time, although it is very low, the possibility of MM should be not excluded even in the parotid duct, and image characteristics should be used for differential diagnosis. In particular, the hyperintense T1 signal shown in MR images can help diagnose MM as a key imaging feature.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

This study was approved by the Institutional Review Board of Seoul National University Dental Hospital (ERI230004). Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.

Author contributions

MA: Conceptualization, Data curation, Methodology, Writing – original draft. J-EK: Data curation, Formal analysis, Investigation, Supervision, Validation, Writing – review & editing. H-JY: Formal analysis, Investigation, Validation, Writing – review & editing. K-HH: Conceptualization, Supervision, Writing – review & editing. W-JY: Supervision, Validation, Writing – review & editing. M-SH: Methodology, Supervision, Writing – review & editing. S-SL: Supervision, Validation, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grant no 08-2019-0004 from the SNUDH Research Fund.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. López F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, et al. Update on primary head and neck mucosal melanoma. Head Neck. (2016) 38:147–55. doi: 10.1002/hed.23872

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Ahadi M, Rakhshan A, Mousavi SR, Saebnoori H. Malignant melanoma of parotid glands from a neglected lesion: A case report. Clin Case Rep. (2021) 9:e04941. doi: 10.1002/ccr3.4941

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Prayson RA, Sebek BA. Parotid gland Malignant melanomas. Arch Pathol Lab Med. (2000) 124:1780–4. doi: 10.5858/2000-124-1780-PGMM

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Ettl T, Irga S, Müller S, Rohrmeier C, Reichert TE, Schreml S, et al. Value of anatomic site, histology and clinicopathological parameters for prediction of lymph node metastasis and overall survival in head and neck melanomas. J Craniomaxillofac Surg. (2014) 42:e252–8. doi: 10.1016/j.jcms.2013.09.007

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Santini H, Byers RM, Wolf PF. Melanoma metastatic to cervical and parotid nodes from an unknown primary site. Am J Surg. (1985) 150:510–2. doi: 10.1016/0002-9610(85)90165-5

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Takeda V. Melanocytes in the human parotid gland. Pathol Int. (1997) 47:581–3. doi: 10.1111/j.1440-1827.1997.tb04545.x

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Greene GW Jr., Bernier JL. Primary Malignant melanomas of the parotid gland. Oral Surg Oral Med Oral Pathol. (1961) 14:108–16. doi: 10.1016/0030-4220(61)90479-0

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Barbieri M, Gentile R, Cordone MP, Mora R, Mora F. Primitive Malignant melanoma of the parotid gland. ORL J Otorhinolaryngol Relat Spec. (2002) 64:297–9. doi: 10.1159/000064131

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Gao N, Li LJ, Li Y, Wang L. Primary amelanotic Malignant melanoma of the parotid gland: a case report. J Int Med Res. (2008) 36:1435–9. doi: 10.1177/147323000803600633

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Chaouki A, Berrada O, Najib Z, Oukessou Y, Abada RA, Rouadi S, et al. Primary Malignant melanoma of the parotid gland: A case report and review of the literature. Ann Med Surg (Lond). (2020) 60:660–3. doi: 10.1016/j.amsu.2020.11.085

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Premkumar A, Marincola F, Taubenberger J, Chow C, Venzon D, Schwartzentruber D. Metastatic melanoma: correlation of MRI characteristics and histopathology. J Magn Reson Imaging. (1996) 6:190–4. doi: 10.1002/jmri.1880060134

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Neville BW, Damm DD, Allen CM, Chi AC. Oral and maxillofacial pathology. 4th ed. Saint Louis: Elsevier (2016) p. 440–66.

Google Scholar

13. Batsakis JG, Bautina E. Metastases to major salivary glands. Ann Otol Rhinol Laryngol. (1990) 99:501–3. doi: 10.1177/000348949009900618

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Botella-Estrada R, Traves V, Requena C, Guillen-Barona C, Nagore E. Correlation of histologic regression in primary melanoma with sentinel node status. JAMA Dermatol. (2014) 150:828–35. doi: 10.1001/jamadermatol.2013.9856

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Woodwards RT, Shepherd NA, Hensher R. Malignant melanoma of the parotid gland: a case report and literature review. Br J Oral Maxillofac Surg. (1993) 31:313–5. doi: 10.1016/0266-4356(93)90068-8

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Apparau D, Apparau H, Mohamad I, Bhavaraju VMK. Malignant melanoma of parotid gland in a child-our unique experience. AME Case Rep. (2018) 2:4. doi: 10.21037/acr

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Villarreal I, Arellano B, Sáenz J, Martin L, Castello J, García-Berrocal J. Primary Malignant parotid melanoma: searching for a rare entity. Int J Otolaryngol Head Neck Surg. (2014) 3:228–32. doi: 10.4236/ijohns.2014.35042

CrossRef Full Text | Google Scholar

18. Bussi M, Cardarelli L, Riontino E, Valente G. Primary Malignant melanoma arising in the parotid gland: case report and literature review. Tumori. (1999) 85:523–5. doi: 10.1177/030089169908500620

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Bahar M, Anavi Y, Abraham A, Ben-Bassat M. Primary Malignant melanoma in the parotid gland. Oral Surg Oral Med Oral Pathol. (1990) 70:627–30. doi: 10.1016/0030-4220(90)90412-L

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Enochs WS, Petherick P, Bogdanova A, Mohr U, Weissleder R. Paramagnetic metal scavenging by melanin: MR imaging. Radiology. (1997) 204:417–23. doi: 10.1148/radiology.204.2.9240529

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Wang BY, Lawson W, Robinson RA, Perez-Ordonez B, Brandwein M. Malignant melanomas of the parotid: comparison of survival for patients with metastases from known vs unknown primary tumor sites. Arch Otolaryngol Head Neck Surg. (1999) 125:635–9. doi: 10.1001/archotol.125.6.635

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Nasri S, Namazie A, Dulguerov P, Mickel R. Malignant melanoma of cervical and parotid lymph nodes with an unknown primary site. Laryngoscope. (1994) 104:1194–8. doi: 10.1288/00005537-199410000-00002

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: parotid gland, malignant melanoma, computed tomography, magnetic resonance imaging, diagnosis

Citation: Aung MTZ, Kim JE, Yoon HJ, Huh KH, Yi WJ, Heo MS and Lee SS (2024) Primary malignant melanoma of the parotid gland, a rare case arising from a duct: a case report and literature review. Front. Oncol. 14:1324214. doi: 10.3389/fonc.2024.1324214

Received: 19 October 2023; Accepted: 17 May 2024;
Published: 06 June 2024.

Edited by:

Jan Baptist Vermorken, University of Antwerp, Belgium

Reviewed by:

Zhi Li, Hubei University of Medicine, China
Gayani Pitiyage, St George’s, University of London, United Kingdom

Copyright © 2024 Aung, Kim, Yoon, Huh, Yi, Heo and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jo-Eun Kim, bm9lbDFzdEBzbnUuYWMua3I=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.